RX-3117 is a small molecule nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers.
Either your just being a pumper or you actually believe your own BS...but to say a pre-clinical compound will result in $10 PPS is pure fantasy. The human trials on that are expected. In fact Rexahn is now almost 2 years late on the start of those trials. So in 5-7 years they may actually develop something if they aren't bankrupt first. Remember the failure or Archexin and Zorexal will com first. Prepare to be diluted son and stop posting total BS so I don't have to come out here and embarrass you with facts.